Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Naxitamab by Y-mAbs Therapeutics for Ewing Sarcoma: Likelihood of Approval
Naxitamab is under clinical development by Y-mAbs Therapeutics and currently in Phase II for Ewing Sarcoma. According to GlobalData, Phase...
Naxitamab by Y-mAbs Therapeutics for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
Naxitamab is under clinical development by Y-mAbs Therapeutics and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to...
Naxitamab by Y-mAbs Therapeutics for Osteosarcoma: Likelihood of Approval
Naxitamab is under clinical development by Y-mAbs Therapeutics and currently in Phase II for Osteosarcoma. According to GlobalData, Phase II...